RxDoctor Payments Data

Christopher Cassisi, MD

Urology · Gainesville, FLNPI 1528084183

Payments from drug & device makers

$5,887in general payments, 2019–2025

Across 292 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$770
  • AbbVie$515
  • Sumitomo Pharma America, Inc.$481
  • Astellas Pharma US Inc$452
  • Coloplast$436
  • Pfizer$377
  • plus $3K from 45 others

What the payments were for

  • Consulting fees$1002%
  • Food & beverage$5,40092%
  • Education$3877%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,887 in reported general payments places this provider in the 55th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$429,623
Medicare patients
1,354
Services billed
6,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron50$45,949
OrgovyxRelugolix13$35,148
Tamsulosin Hcl819$16,694
Testosterone33$10,355
Finasteride416$6,817
Testosterone Cypionate128$6,122
Dutasteride70$2,777
Silodosin30$2,091
Oxybutynin Chloride91$1,819
Tadalafil21$1,806
Methenamine Hippurate19$1,715
Potassium Citrate ErPotassium Citrate19$1,287
Alfuzosin Hcl ErAlfuzosin Hcl52$1,029
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$851
Bethanechol Chloride24$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$452$45,94950 claims
Sumitomo Pharma America, Inc.Orgovyx$481$35,14813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 935 urology providers in Florida.

Other urology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →